1. Home
  2. IKT vs SY Comparison

IKT vs SY Comparison

Compare IKT & SY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.65

Market Cap

274.9M

Sector

Health Care

ML Signal

HOLD

Logo So-Young International Inc. American Depository Shares

SY

So-Young International Inc. American Depository Shares

HOLD

Current Price

$2.24

Market Cap

276.7M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
IKT
SY
Founded
2008
2013
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
274.9M
276.7M
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
IKT
SY
Price
$1.65
$2.24
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
2
Target Price
$5.55
★ $7.31
AVG Volume (30 Days)
★ 559.3K
312.6K
Earning Date
11-13-2026
11-16-2026
Dividend Yield
N/A
★ 1.17%
EPS Growth
★ 57.76
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$34.60
Revenue Next Year
$33.33
$36.03
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.33
$1.28
52 Week High
$2.61
$4.75

Technical Indicators

Market Signals
Indicator
IKT
SY
Relative Strength Index (RSI) 25.79 33.38
Support Level $1.59 $2.18
Resistance Level $1.74 $2.38
Average True Range (ATR) 0.11 0.13
MACD -0.03 -0.06
Stochastic Oscillator 4.85 4.07

Price Performance

Historical Comparison
IKT
SY

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

About SY So-Young International Inc. American Depository Shares

So-Young International Inc is an aesthetic treatment platform in China connecting consumers with online services and offline treatments. Its online platform operates across multiple access points, including mobile app, Weixin mini program, and soyoung.com website, where both consumers and aesthetic practitioners can access media content, an engaging social community and a transparent reservation system. The company has four reportable segments: Aesthetic treatment services group, Platform service group, Wuhan Miracle, and Others. The majority of revenue is derived from the Platform service group, which generates revenue by providing information services and reservation services. All the company's revenues are derived from within the PRC.

Share on Social Networks: